Kedrion Honored at Healthcare Innovation Celebration

FORT LEE, N.J., Oct. 6, 2026 /CourierPR/ -- Kedrion Biopharma, the world's fifth-largest player in plasma-derived products, will be honored at the Innovation Celebration at the 2026 Breakthroughs Conference and Exhibition, which is entering its 15th year of recognizing and honoring healthcare supplier innovation. More than 600 suppliers will exhibit at the Breakthroughs Conference, and the Innovation Celebration will recognize groundbreaking healthcare technologies launched throughout the year.

This year, Kedrion Biopharma will be honored for its newest product, QIVIGY®, which has been recognized for its innovative approach to treating adults with primary humoral immunodeficiency (PI). Approved by the U.S. Food and Drug Administration in 2025, QIVIGY is a 10% immune globulin (Ig) solution that is indicated for the treatment of adults with primary humoral immunodeficiency.

Kedrion Biopharma, which employs approximately 5,400 people worldwide, operates plasma collection centers in the United States and the Czech Republic. The company's portfolio of 39 products is distributed in over 100 countries, making it a significant player in the global healthcare industry.

QIVIGY is a 10% immune globulin (Ig) solution that is indicated for the treatment of adults with primary humoral immunodeficiency. Developed, manufactured, and released through Kedrion's integrated global network, QIVIGY reflects the company's continued investment in generating clinical evidence and advancing immunoglobulin therapy to meet the needs of patients.

The Innovation Celebration, which is entering its 15th year, is a significant event in the healthcare industry. It recognizes and honors suppliers who have made groundbreaking contributions to healthcare innovation. Kedrion Biopharma's recognition at this event underscores the company's commitment to advancing patient care and meaningful healthcare innovation.

Premier, the organization hosting the Innovation Celebration, is a leading technology-driven healthcare improvement company. The company unites providers, suppliers, and payers to make healthcare better with national scale, actionable intelligence, and novel technologies. Headquartered in Charlotte, North Carolina, Premier offers integrated data and analytics, collaboratives, supply chain solutions, advisory services, and other solutions in service of their mission to improve the health of communities.

Kedrion Biopharma's QIVIGY solution, which is indicated for the treatment of adults with primary humoral immunodeficiency, is a testament to the company's commitment to pairing scientific innovation with patient-based quality outcomes. The company's continued investment in clinical research reflects its commitment to further evaluating QIVIGY and exploring how immunoglobulin therapy may address important unmet needs across a broader range of patients.